Japan In-Vitro Diagnostics Market (by Segment and Company), Size, Share, Major Deals, Trends, Company Analysis and Recent Developments - Forecast to 2030

Japan's in-vitro diagnostics market is predicted to reach US$ 6.62 Billion by 2030, from US$ 4.59 Billion in 2023. Japan is one of the leading in-vitro diagnostics markets in the Asia-Pacific region. In-vitro diagnostics refers to the diagnosis of disease or other conditions of the human body through the collection, preparation, and testing of human samples with reagents, instruments, and systems.

Japan is facing the challenges of fighting infectious diseases including HBV, TB, HCV, and HIV, as well as various chronic diseases and cancer. The population of Japan is aging rapidly. For instance, as of September 2023, close to 36.23 million people in Japan were estimated to be within the age group of 65 and over. Japan’s quickly aging population leads to an explosion of chronic conditions such as heart disease and cancer. All of these conditions can be diagnosed and monitored using IVD products. However, some of the factors limiting the growth of the market are a lack of proper reimbursement policies and a stringent regulatory framework.

Japan In-Vitro Diagnostics (IVD) Market - Recent Developments

• In January 2024, bioMérieux announced the acquisition of LUMED, a software company that has developed a clinical decision support system to help hospitals optimize antimicrobial prescriptions and monitor healthcare-associated infections.
• In August 2023, Sysmex Corporation announced an expansion of the Global Business Partnership Agreement (GBPA) with Roche Diagnostics International Ltd.
• In April 2023, Oxford Nanopore Technologies plc, and bioMérieux SA teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.
• In October 2023, Sysmex and Fujirebio entered into a business collaboration agreement in the field of immunoassay, in a bid to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay.
• In December 2022, bioMérieux announced the CE-marking of VIDAS KUBE, the next-generation automated immunoassay system for the VIDAS range.

By Segment: Japan IVD Market and Forecast - Key Takeaways

• On a segment basis, immunology and genetic testing are the leading segments of the Japan IVD market.
• Genetic Testing is the fastest-growing segment of the Japanese in-vitro diagnostics market.
• Tumor Marker and Hematology segments are competing closely with each other to grab the maximum share of the pie.
• The growth of the hematology market is attributed to factors such as the increasing incidences of blood disorders, the growing adoption of automated hematology instruments by diagnostic laboratories, the emergence of high throughput hematology analyzers, and the introduction of technologically advanced hematology instruments.
• Microbiology testing is witnessing growth due to technological advancements and increasing infectious disease incidences.

Japan IVD Market - Company Analysis

• In the Japan IVD market, Roche Diagnostics and Sysmex Corporation are the leading players.
• Thermo Fisher Scientific Inc., Danaher Corporation, Abbott Laboratories, and Biomerieux are the other top four players in the Japan IVD market.
• In the diagnostics business, Abbott will focus on driving sales growth from its Alinity suite of diagnostics instruments and its portfolio of rapid diagnostic testing systems.
• In August 2023, Sysmex Corporation announced an expansion of the Global Business Partnership Agreement (GBPA) with Roche Diagnostics International Ltd.
• In April 2023, bioMérieux submitted a 510(k) premarket notification to the U.S. FDA for the VITEK REVEAL, formerly known as SPECIFIC REVEAL Rapid AST System.
• In October 2023, Sysmex and Fujirebio entered into a business collaboration agreement in the field of immunoassay, in a bid to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay.

The report provides a comprehensive assessment of the fast-evolving, high-growth Japan IVD Market.

This 218 Pages report with 42 Figures and 4 Tables has been analyzed from 8 View Points:

1) Japan In-Vitro Diagnostics (IVD) Market and Forecast (2008 - 2030)
2) Japan IVD Market Share and Forecast (2008 - 2030)
3) Japan IVD Market & Forecast - By Segment (2008 - 2030)
4) Japan IVD Market & Forecast - Company Sales Analysis (2014 - 2030)
5) In-Vitro Diagnostics (IVD) Market - Major Deals
6) In-Vitro Diagnostics (IVD) Market - Recent Developments
7) Registration for In Vitro Diagnostic Devices in Japan
8) Japan IVD Market - Market Dynamics

Japan In-Vitro Diagnostics Market - By Segment

1. Urine & Feces
2. Hematology
3. Clinical Chemistry
4. SMBG
5. Tumor Marker
6. Immunoassay
7. Infectious Disease
8. Microbiology
9. Pathology
10. Genetic Testing
11. Others

Japan In-Vitro Diagnostics Market - Company Analysis

1. Roche Diagnostics
2. Abbott Laboratories
3. Danaher Corporation
4. bioMérieux S.A.
5. Sysmex Corporation
6. Bio-Rad Laboratories, Inc.
7. Becton Dickinson Company
8. Thermo Fisher Scientific Inc.
9. Others

Data Source

The publisher employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from the Proprietary Information Database, Primary and Secondary Research Methodologies, and In-house analysis by a dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interviews, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine, and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Reports, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.